Company Description
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.
Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease.
The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001.
Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Country | United States |
Founded | 2016 |
IPO Date | Jun 15, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 7 |
CEO | Stephan Jackman |
Contact Details
Address: 3480 Peachtree Road NE, Second Floor, Suite 103 Atlanta, Georgia 30326 United States | |
Phone | 844 722 6333 |
Website | alzamend.com |
Stock Details
Ticker Symbol | ALZN |
Exchange | NASDAQ |
Fiscal Year | May - April |
Reporting Currency | USD |
IPO Price | $5.00 |
CIK Code | 0001677077 |
CUSIP Number | 02262M308 |
ISIN Number | US02262M4078 |
Employer ID | 81-1822909 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Stephan Jackman | Chief Executive Officer and Director |
Milton Charles Ault III | Founder and Vice Chairman |
David J. Katzoff | Chief Financial Officer |
Henry C. W. Nisser Esq. | Executive Vice President, General Counsel and Director |
Kenneth S. Cragun CPA | Senior Vice President of Finance |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Oct 15, 2024 | 8-K | Current Report |
Oct 3, 2024 | 424B5 | Filing |
Oct 3, 2024 | 8-K | Current Report |
Sep 11, 2024 | 10-Q | Quarterly Report |
Jul 31, 2024 | 8-K | Current Report |
Jul 30, 2024 | 10-K | Annual Report |
Jul 30, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
Jul 12, 2024 | 8-K | Current Report |
Jul 10, 2024 | 424B3 | Prospectus |
Jul 9, 2024 | EFFECT | Notice of Effectiveness |